Lymphocytic choriomeningitis virus (LCMV) infection of macaques : a model for Lassa fever
Copyright © 2011 Elsevier B.V. All rights reserved..
Arenaviruses such as Lassa fever virus (LASV) and lymphocytic choriomeningitis virus (LCMV) are benign in their natural reservoir hosts, and can occasionally cause severe viral hemorrhagic fever (VHF) in non-human primates and in human beings. LCMV is considerably more benign for human beings than Lassa virus, however certain strains, like the LCMV-WE strain, can cause severe disease when the virus is delivered as a high-dose inoculum. Here we describe a rhesus macaque model for Lassa fever that employs a virulent strain of LCMV. Since LASV must be studied within Biosafety Level-4 (BSL-4) facilities, the LCMV-infected macaque model has the advantage that it can be used at BSL-3. LCMV-induced disease is rarely as severe as other VHF, but it is similar in cases where vascular leakage leads to lethal systemic failure. The LCMV-infected macaque has been valuable for describing the course of disease with differing viral strains, doses and routes of infection. By monitoring system-wide changes in physiology and gene expression in a controlled experimental setting, it is possible to identify events that are pathognomonic for developing VHF and potential treatment targets.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
---|---|
Enthalten in: |
Antiviral research - 92(2011), 2 vom: 06. Nov., Seite 125-38 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zapata, Juan C [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 08.02.2012 Date Revised 03.06.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.antiviral.2011.07.015 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM210547332 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM210547332 | ||
003 | DE-627 | ||
005 | 20231224011847.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.antiviral.2011.07.015 |2 doi | |
028 | 5 | 2 | |a pubmed24n0702.xml |
035 | |a (DE-627)NLM210547332 | ||
035 | |a (NLM)21820469 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zapata, Juan C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lymphocytic choriomeningitis virus (LCMV) infection of macaques |b a model for Lassa fever |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.02.2012 | ||
500 | |a Date Revised 03.06.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2011 Elsevier B.V. All rights reserved. | ||
520 | |a Arenaviruses such as Lassa fever virus (LASV) and lymphocytic choriomeningitis virus (LCMV) are benign in their natural reservoir hosts, and can occasionally cause severe viral hemorrhagic fever (VHF) in non-human primates and in human beings. LCMV is considerably more benign for human beings than Lassa virus, however certain strains, like the LCMV-WE strain, can cause severe disease when the virus is delivered as a high-dose inoculum. Here we describe a rhesus macaque model for Lassa fever that employs a virulent strain of LCMV. Since LASV must be studied within Biosafety Level-4 (BSL-4) facilities, the LCMV-infected macaque model has the advantage that it can be used at BSL-3. LCMV-induced disease is rarely as severe as other VHF, but it is similar in cases where vascular leakage leads to lethal systemic failure. The LCMV-infected macaque has been valuable for describing the course of disease with differing viral strains, doses and routes of infection. By monitoring system-wide changes in physiology and gene expression in a controlled experimental setting, it is possible to identify events that are pathognomonic for developing VHF and potential treatment targets | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Pauza, C David |e verfasserin |4 aut | |
700 | 1 | |a Djavani, Mahmoud M |e verfasserin |4 aut | |
700 | 1 | |a Rodas, Juan D |e verfasserin |4 aut | |
700 | 1 | |a Moshkoff, Dmitry |e verfasserin |4 aut | |
700 | 1 | |a Bryant, Joseph |e verfasserin |4 aut | |
700 | 1 | |a Ateh, Eugene |e verfasserin |4 aut | |
700 | 1 | |a Garcia, Cybele |e verfasserin |4 aut | |
700 | 1 | |a Lukashevich, Igor S |e verfasserin |4 aut | |
700 | 1 | |a Salvato, Maria S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 92(2011), 2 vom: 06. Nov., Seite 125-38 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
773 | 1 | 8 | |g volume:92 |g year:2011 |g number:2 |g day:06 |g month:11 |g pages:125-38 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2011.07.015 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 92 |j 2011 |e 2 |b 06 |c 11 |h 125-38 |